Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?

Ayoub Charehbili; Duveken B Y Fontein; Judith R Kroep; Gerrit-Jan Liefers; Johannes W R Nortier; Cornelis J H van de Velde

doi:10.3390/jcm2040188

Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?

J Clin Med. 2013 Oct 16;2(4):188-200. doi: 10.3390/jcm2040188.

Authors

Ayoub Charehbili^{1

2}, Duveken B Y Fontein³, Judith R Kroep⁴, Gerrit-Jan Liefers⁵, Johannes W R Nortier⁶, Cornelis J H van de Velde⁷

Affiliations

¹ Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. a.charehbili@lumc.nl.
² Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. a.charehbili@lumc.nl.
³ Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. d.b.y.fontein@lumc.nl.
⁴ Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. j.r.kroep@lumc.nl.
⁵ Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. g.j.liefers@lumc.nl.
⁶ Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. j.w.r.nortier@lumc.nl.
⁷ Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. c.j.h.van_de_velde@lumc.nl.

Abstract

The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs might play a role in neoadjuvant treatment of women with breast cancer.

Keywords: bisphosphonates; chemotherapy; neoadjuvant; postmenopausal; zoledronic acid.